Previous 10 | Next 10 |
2024-03-30 06:50:00 ET The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them. Three Motley Fool contributors believe they've identified three stocks that fit the bill. Here's why they think CRISPR Therapeutics...
2024-03-28 09:06:17 ET “Biotech industry has found its footing again”, says Karen Andersen – a Morningstar strategist. Here are the top U.S. based stocks within this space that are particularly worth owning for 2024. Vertex Pharmaceuticals Inc (NASDAQ: VRTX) ...
2024-03-26 16:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-26 13:23:00 ET Summary Florida signs bill requiring parental consent for minors to create social media accounts and bans children under 14 from joining social media. McDonald’s will start selling Krispy Kreme doughnuts this year. Overbought conditions flash acro...
2024-03-26 11:43:00 ET More on CRISPR Technology Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) Editas Medicine, Inc. (EDIT...
2024-03-26 02:33:22 ET Summary Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available for CASGEVY in approved countries. Private insur...
2024-03-21 08:28:21 ET More on Vertex Pharmaceuticals Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth Vertex Pharmaceuticals Incorporated (VRTX) Leerink Partners Global Biopharma Conference (Transcript) Vertex Pharmaceuticals Incorporated (V...
– ADPKD is the most common inherited kidney disease, with no treatments currently available that address the underlying cause of disease – – Vertex to initiate a Phase 1 clinical trial in healthy volunteers this month – – ADPKD is Vertex’s...
2024-03-21 00:00:46 ET Summary Vertex Pharmaceuticals has a dominant Cystic fibrosis franchise and plans to launch five new products by 2028, including a next-generation CF drug and a non-opioid pain management drug. VRTX stock has stalled in 2024 due to lower revenue growth proje...
2024-03-18 11:02:46 ET More on bluebird bio Bluebird Bio: Innovative Therapies, Monetary Setbacks Biotech And Pharma Diversification Pays Off bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD Biggest stock movers today: EQT, MESO, Crypto...
News, Short Squeeze, Breakout and More Instantly...
Vertex Pharmaceuticals Incorporated Company Name:
VRTX Stock Symbol:
NASDAQ Market:
Vertex Pharmaceuticals Incorporated Website:
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations Canada NewsWire -Approximately 200 people with certain rare CF mutations are now ...